Home/Filings/4/0000899243-19-013251
4//SEC Filing

VANLENT ANNE 4

Accession 0000899243-19-013251

CIK 0001563880other

Filed

May 12, 8:00 PM ET

Accepted

May 13, 5:00 PM ET

Size

11.1 KB

Accession

0000899243-19-013251

Insider Transaction Report

Form 4
Period: 2019-05-09
VANLENT ANNE
Director
Transactions
  • Conversion

    Common Stock

    2019-05-09+20,98320,983 total
  • Conversion

    Series C Preferred Stock

    2019-05-0947,8070 total
    Common Stock (5,582 underlying)
  • Purchase

    Common Stock

    2019-05-09$10.00/sh+5,000$50,00025,983 total
  • Conversion

    Series A Preferred Stock

    2019-05-09107,9770 total
    Common Stock (15,401 underlying)
Footnotes (2)
  • [F1]On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
  • [F2]On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

Issuer

Trevi Therapeutics, Inc.

CIK 0001563880

Entity typeother

Related Parties

1
  • filerCIK 0001229243

Filing Metadata

Form type
4
Filed
May 12, 8:00 PM ET
Accepted
May 13, 5:00 PM ET
Size
11.1 KB